Rita Leporati (@ritalepp) 's Twitter Profile
Rita Leporati

@ritalepp

Medical Oncologist, thoracic malignancies @IstTumori

ID: 484620881

calendar_today06-02-2012 09:40:26

60 Tweet

527 Followers

506 Following

Mariana Brandao (@marianabrandao0) 's Twitter Profile Photo

What a joy to have these Young & Early Career Investigators of the EORTC Lung Cancer Group 🫁coming from so many different countries to exchange knowledge, finally meet F2F and relax together during #ESMO24 Thanks to Anne-Marie Dingemans and the LCG Board for all of your support! 🙏

What a joy to have these Young &amp; Early Career Investigators of the <a href="/EORTC/">EORTC</a> Lung Cancer Group 🫁coming from so many different countries to exchange knowledge, finally meet F2F and relax together during #ESMO24
Thanks to <a href="/Dingemans_AnneM/">Anne-Marie Dingemans</a> and the LCG Board for all of your support! 🙏
Sara Manglaviti (@saramanglaviti) 's Twitter Profile Photo

Can Bone Targeted Agents’ use enhance ICI efficacy in aNSCLC pts with bone mets? ➡️ Take a look to out study on Lung Cancer Journal showing a survival benefit upon concomitant #ICI and #denosumab administration in #aNSCLC pts with high bone tumor burden #HBTB Roberto Ferrara

Can Bone Targeted Agents’ use enhance ICI efficacy in aNSCLC pts with bone mets? 

➡️ Take a look to out study on <a href="/LungCaJournal/">Lung Cancer Journal</a> showing a survival benefit upon concomitant #ICI and #denosumab administration in #aNSCLC pts with high bone tumor burden #HBTB 

<a href="/RobertoFerrara_/">Roberto Ferrara</a>
Achille Bottiglieri (@achillebott91) 's Twitter Profile Photo

It was a great honor for me today to discuss the PEANUT trial update to #AIOM. Pembrolizumab + nab-paclitaxel confirmed a significant efficacy in #mUC over 4 years of mFUP. ‼️ORR 50.0%; DCR 75.8% ‼️mPFS 5.1 mo; mOS 11.0 mo My thanks to the GU Oncology Team of Istituto Tumori

It was a great honor for me today to discuss the PEANUT trial update to #AIOM. Pembrolizumab + nab-paclitaxel confirmed a significant efficacy in #mUC over 4 years of mFUP.
‼️ORR 50.0%; DCR 75.8%
‼️mPFS 5.1 mo; mOS 11.0 mo
My thanks to the GU Oncology Team of <a href="/IstTumori/">Istituto Tumori</a>
Chiara Corti (@ccortimd) 's Twitter Profile Photo

Evidence on immune predictors is fragmented, thus requiring caution. That said, this retrospective study highlights early modifications of lymphocyte counts on CDK4/6i-ET are associated w/ better PFS & OS in pts w/ met HR+/HER2− #breastcancer shorturl.at/zBGM8 Therapeutic Advances in Medical Oncology

Evidence on immune predictors is fragmented, thus requiring caution. That said, this retrospective study highlights early modifications of lymphocyte counts on CDK4/6i-ET are associated w/ better PFS &amp; OS in pts w/ met HR+/HER2− #breastcancer shorturl.at/zBGM8 <a href="/TAMedOncol/">Therapeutic Advances in Medical Oncology</a>
arsela prelaj (@prelajarsela) 's Twitter Profile Photo

APOLLO 11 Project, Consortium in Advanced #Lung #Cancer Patients Treated With #Innovative #Therapies: Integration of Real-World Data and Translational Research - Clinical Lung Cancer using #ArtificialIntelligence to analyze the data. #datadriven #model clinical-lung-cancer.com/article/S1525-…

Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation (@rmanochakian) 's Twitter Profile Photo

🚨The future of #ThoracicOncology is in great hands! My co-chair colleague Dr Christian Rolfo, myself, great faculty mentors, & #IASLC staff are honored to kick off the: “2024 global IASLC #Academy.” Welcome to an outstanding group of #EarlyCareer #Physicians & #Researchers.

🚨The future of #ThoracicOncology is in great hands!

My co-chair colleague Dr <a href="/ChristianRolfo/">Christian Rolfo</a>, myself, great faculty mentors, &amp; #IASLC staff are honored to kick off the:

“2024 global <a href="/IASLC/">IASLC</a> #Academy.”

Welcome to an outstanding group of #EarlyCareer #Physicians &amp; #Researchers.
Charles Swanton (@charlesswanton) 's Twitter Profile Photo

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24, out in Cancer Discovery today rb.gy/q484j9 Tweetorial👇

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24, out in <a href="/CD_AACR/">Cancer Discovery</a> today rb.gy/q484j9 Tweetorial👇
Rita Leporati (@ritalepp) 's Twitter Profile Photo

FLAURA2 exploratory analysis discussion by Marina Garassino at #AACR24: 🔺dynamic ctDNA analysis not useful for clinical decisions 🔹baseline detection of EGFRm is prognostic and may select for a higher degree of clinical benefit from Osi+CT AACR

FLAURA2 exploratory analysis discussion by <a href="/marinagarassino/">Marina Garassino</a> at #AACR24:
🔺dynamic ctDNA analysis not useful for clinical decisions
🔹baseline detection of EGFRm is prognostic and may select for a higher degree of clinical benefit from Osi+CT
<a href="/AACR/">AACR</a>
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

Congratulations to all of these IASLC Academy participants - early-career physicians interested in academic careers in thoracic oncology, partnered with expert mentors through the year. Looking forward to seeing all that you do!

Congratulations to all of these <a href="/IASLC/">IASLC</a> Academy participants - early-career physicians interested in academic careers in thoracic oncology, partnered with expert mentors through the year. Looking forward to seeing all that you do!
Benjamin Besse (@benjaminbessemd) 's Twitter Profile Photo

LIFETIME osimertinib after a treatment with curative intent? In pts with EGFRmut stage III NSCLC, chemo-radiotherapy can CURE pts. Were pts in LAURA properly staged by petscan/brain RMI? Why not using MRD to select patient? Strong concerns when OS is not positive. #ASCO24

LIFETIME osimertinib after a treatment with curative intent?
In pts with EGFRmut stage III NSCLC, chemo-radiotherapy can CURE pts.
Were pts in LAURA properly staged by petscan/brain RMI?
Why not using MRD to select patient?
Strong concerns when OS is not positive.  #ASCO24
Charles Swanton (@charlesswanton) 's Twitter Profile Photo

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in Nature Communications. nature.com/articles/s4146… 🧵

Rita Leporati (@ritalepp) 's Twitter Profile Photo

Don’t miss the V edition of the #CocktailWithScience #LungCancer meeting in Milan🫁 👉🏻 lungcancer-milan.com Hosted by Giuseppe Lo Russo with a world-class faculty

Don’t miss the V edition of the #CocktailWithScience #LungCancer meeting in Milan🫁

👉🏻 lungcancer-milan.com

Hosted by <a href="/GLoRussoMD_PhD/">Giuseppe Lo Russo</a> with a world-class faculty
Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation (@rmanochakian) 's Twitter Profile Photo

🚨🔥The future of #ThoracicOncology is in GREAT hands! The final meeting of the 2024 IASLC #Academy with this OUTSTANDING group of #EarlyCareer #Physicians & #Researchers at #WCLC24. Honored to serve as academy co-chair with my amazing friend Christian Rolfo & GREAT faculty.

🚨🔥The future of #ThoracicOncology is in GREAT hands!

The final meeting of the 2024 <a href="/IASLC/">IASLC</a> #Academy with this OUTSTANDING group of #EarlyCareer #Physicians &amp; #Researchers at #WCLC24.

Honored to serve as academy co-chair with my amazing friend <a href="/ChristianRolfo/">Christian Rolfo</a> &amp; GREAT faculty.